GE8820
Autoimmune diseases driven by pathogenic IgG4 autoantibodies
Pre-clinicalActive
Key Facts
Indication
Autoimmune diseases driven by pathogenic IgG4 autoantibodies
Phase
Pre-clinical
Status
Active
Company
About GlycoEra
GlycoEra is a private, pre-clinical-stage biotech developing extracellular protein degraders for autoimmune diseases. Its proprietary platform enables deep (>95%), rapid (under 30 minutes), and selective degradation of pathogenic proteins like autoantibodies without causing broad immunosuppression. The company is advancing its lead program, GE8820, targeting pathogenic IgG4 autoantibodies, and has raised significant capital ($130M) to validate its platform and pipeline.
View full company profile